Gaglione, Erika M.

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Sun, C., Nierman, P., Kendall, E. K., Cheung, J., Gulrajani, M., Herman, S. E. M., Pleyer, C., Ahn, I. E., Stetler-Stevenson, M., Yuan, C. M., et al. (2020) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 103

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 43

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Zhang, D., Harris, H. M., Chen, J., Judy, J., James, G., Kelly, A., McIntosh, J., Tenn-McClellan, A., Ambing, E., Tan, Y. S., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 35

BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL

Mhibik, M., Gaglione, E. M., Eik, D., Kendall, E. K., Blackburn, A., Keyvanfar, K., Baptista, M. J., Ahn, I. E., Sun, C., Qi, J., et al. (2021) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 30

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy

Alsadhan, A., Chen, J., Gaglione, E. M., Underbayev, C., Tuma, P. L., Tian, X., Freeman, L. A., Baskar, S., Nierman, P., Soto, S., et al. (2023) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 23